DCF Method | Discounted Cash Flow Method | Value

With the DCF method, you calculate the value of a company. An example.

Siert Bruins Siert Bruins is the author of this webpage
discounted cash flow method dcf for startup valuation What is the DCF method? To discuss the more advanced methods for business valuation, we first need to introduce the DCF method (Discounted Cash Flow method) here. The DCF method is a commonly used technique to determine the value of a startup or a larger company by looking at the cash flow in the future. On the page about discount rate: the present value of future money, we have seen when calculating interest income, the future value of a certain amount grows by a factor (1 + r)n. However, a more common question is what the value is of several amounts that will be paid out on different future dates. The DCF method can help with that. Using the formula above, we have calculated how much a future amount to be received in a certain period n is worth in "today's money," namely:
DCF method image1
We will now expand on this principle as follows. Suppose you expect a number of cash flows (CF) from year one (t = 1) to year n (t = n), that is, CF1 to CFn, by investing an amount CF0. What is the total value, or Net Present Value (NPV), of these expected cash flows? This is calculated by discounting each cash flow and summing it all up at the end. This is done as follows: DCF Method image2

So, this is the DCF method, or discounted cash flow method, and it is the most important of all methods for a financial analyst. This method is therefore also important for those who want to evaluate an invention, and that is why we will go into detail here and illustrate how you can easily calculate an NPV with a spreadsheet.

Looking at the formula above, we see that there are a number of unknowns that we need to know before we can apply the formula, namely the cash flows (CF 0 to CF n ) and the discount rate r. We start with the latter.

Capital Asset Pricing Model and the discount rate r

So far, we have taken the discount rate, r, as interest and chosen it to make calculations easier. However, it becomes much more difficult to figure out what value to take for r when valuing a company. Before we proceed, we need to define what r actually represents.

We can illustrate this with the NPV formula. Suppose you receive two proposals.

Proposal 1 is to deposit $100 for five years in an account at a well-known bank on the corner of the street at an interest rate of 4%. So, you receive four interest payments of $4 each and a payment of $104 in year five ($4 + the invested amount, $100, also known as the principal).

Proposal 2 is to invest the same amount in a biotechnology company. In return, you receive $7 for four years and in year five, $107. Which proposal would you choose?

At first glance, this seems like an easy question to answer, and you're inclined to go with proposal 2; after all, you get more money for the same investment. But is this really the case, and how can we find out? The answer is provided by the Capital Asset Pricing Model (CAPM). CAPM is one of the most important cornerstones of finance and is used to calculate the required return for a specific investment in a particular project or company (on another page you can read more information about return and its definitions). It is calculated using the following formula:

r i = R f + βi(R m - R f )

where

  1. r i is the discount rate or required return, also known as cost of capital or expected return, for a specific investment, project, company, etc. We will use these terms interchangeably.
  2. R f is the risk-free rate.
  3. R m is the return of the (market) portfolio, and
  4. βi is the risk associated with a specific company, project i, etc.

In the following page about the Capital Asset Pricing Model (CAPM), we will continue to answer the question of whether you should invest your money in the bank or in a risky biotechnology company.

About Siert Bruins

Siert Bruins, PhD

Hello! I'm Siert Bruins, a Dutch entrepreneur and founder of a.o. Life2Ledger B.V. With a background in Medical Biology and a Ph.D. in clinical diagnostics from the University of Groningen, the Netherlands, I've spent decades in the world of innovation, especially at the intersection of Universities, Companies, and Academic Hospitals in the fields of life Sciences, Healthcare, and Technology. Since 2009, I've been running the Dutch version of this website, sharing insights for aspiring entrepreneurs, and have recently expanded to an international audience with the English version, Technoventure.eu. My work focuses on the development and validation of medical devices, including sensors for home diagnostics, as well as using blockchain technology to ensure the authenticity and provenance of medical datasets for AI applications. To put it bluntly: how can you be sure that you train, validate, test and use your algorithms with the datasets that you believe to be the right ones? I've had the privilege of navigating the entrepreneurial journey, learning from both successes and failures. My current project, Life2Ledger, aims to support healthcare data integrity with blockchain technology, offering solutions to ensure the trustworthiness of datasets in decentralized health systems. I believe that innovation is about learning through experience and I'm open to sharing my experiences with others. If you're interested in connecting, feel free to visit my LinkedIn profile. or follow my updates on X.